Uninhibited Neurogenic Bladder Treated with Prazosin

Jensen, Ditlev

doi:10.3109/00365598109179608

Cited by 61 publications

(19 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean posterior urethral pres sure fell from 27.7 to 12.4 cm H20 and the mean urethral diameter increased from 3.9 to 10.6 mm. Detrusor pressure was not significantly reduced after alfuzosin (data not shown) as previously reported by others with prazosin (Jensen, 1981a).…”

Section: Resultssupporting

confidence: 89%

Bladder-neck opening test in spinal cord injury patients using a new i.v. alpha-blocking agent, alfuzosin

et al. 1989

View full text Add to dashboard Cite

SUIIlIIlaryA bladder-neck opening test using alfuzosin, a new alpha-adrenoceptor blocking agent, was carried out in 21 patients with spinal cord injury. The efficacy of alJuzo sin was assessed with 4 simple urodynamic parameters: micturition, residual urine, posterior urethral pressure and diameter. Both mean urethral pressure and diameter were significantly affected after the administration of 5 mg i.v. alJuzosin. The test was clinically positive in 18 patients: 11 out of 13 patients using intermittent cath eterisation or continuous drainage urinated and 6 out of 8 patients already tapping had reduced residual urine volumes. A decrease in posterior urethral pressure was also observed in 2 out of 3 patients who did not respond clinically to alJuzosin.AlJuzosin was well tolerated during this test. Oral alfuzosin should therefore be investigated in patients who gave a satisfactory response to such a test.

show abstract

Section: Resultssupporting

confidence: 89%

Bladder-neck opening test in spinal cord injury patients using a new i.v. alpha-blocking agent, alfuzosin

et al. 1989

View full text Add to dashboard Cite

show abstract

“…Prazosin, one of the specific postsynaptic a-adrenoceptor blocking agents, was reported to increase BC markedly and diminish the uninhibited detrusor contraction in neurogenic bladder when administered orally (Jensen 1981). The present study also suggested that prazosin could be available to control detrusor hyperreflexia by intravesical instillation.…”

Section: Discussionmentioning

confidence: 99%

Effects of Intravesically Administered Anticholinergics, .BETA.-Adrenergic Stimulant and .ALPHA.-Adrenergic Blocker on Bladder Function in Unanesthetized Rats.

Ukimura

1993

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

“…Hence, Prazosin, a selective alpha I adrenergic blocking agent with less side effects, has a documented action on the urethra (Kiruluta et al, 1981), and has been employed by Jensen with good results in four out of five patients with uninhibited bladder (Jensen, 1981).…”

Section: Discussionmentioning

confidence: 99%

Nicergoline in the treatment of neuropathic bladder dysfunction: a preliminary report

Gállego¹,

Forner²,

Jiménez³

et al. 1984

Spinal Cord

View full text Add to dashboard Cite

Summary. We have employed the alpha blocking drug Nicergoline in 14 patients with neuropathic bladder dysfunction of the upper motor neurone type.The oral administration of 15-30 mgrs/ day of this drug over a period of 9·5 months significantly improved the urodynamic parameters, with an increase of bladder capacity, a disappearance or amelioration of uninhibited bladder contrac tions and a decrease in urethral pressure, profile urethral length and residual urine.Two patients with vesico-ureteral reflux present before treatment showed radiological improvement after Nicergoline administration.Tolerance of Nicergoline had been excellent without appreciable side effects. In conclusion, Nicergoline seems to be active and well tolerated in the pharmaco logical treatment of neuropathic bladder dysfunction.

show abstract

Uninhibited Neurogenic Bladder Treated with Prazosin

Cited by 61 publications

References 13 publications

Bladder-neck opening test in spinal cord injury patients using a new i.v. alpha-blocking agent, alfuzosin

Bladder-neck opening test in spinal cord injury patients using a new i.v. alpha-blocking agent, alfuzosin

Effects of Intravesically Administered Anticholinergics, .BETA.-Adrenergic Stimulant and .ALPHA.-Adrenergic Blocker on Bladder Function in Unanesthetized Rats.

Nicergoline in the treatment of neuropathic bladder dysfunction: a preliminary report

Contact Info

Product

Resources

About